Natco Pharma invests $14M in eGenesis
Analysis based on 6 articles · First reported Aug 25, 2026 · Last updated Aug 25, 2026
The investment signals Natco Pharma's strategic expansion into innovative biotechnology, potentially enhancing its long-term growth prospects despite short-term stock decline. The market reaction was mildly negative, reflecting investor caution over the company's recent USFDA inspection observations and broader sector headwinds.
Natco Pharma announced on August 25, 2026 that it is investing an additional $14 million in eGenesis, a US-based biotechnology company developing genome-engineered transplantable organs. The investment is made through two wholly-owned subsidiaries: Natco Pharma will invest $9.5 million and Natco Pharma will invest $4.5 million, via convertible promissory notes carrying an 8% annual compounded interest rate. This brings Natco's total investment in eGenesis to $22 million, following an earlier $8 million investment in 2024 through preferred stock. The investment is aimed at supporting eGenesis's programmes for porcine kidney, liver, and heart transplantation, which address the global organ shortage. eGenesis has reported successful porcine kidney transplants in living patients, authorized by the US United States — Food and Drug Administration under the Expanded Access pathway. The completion date for the investment is expected around September 30, 2026. Natco Pharma's shares closed 1.92% lower at ₹866.45 on the Bombay Stock Exchange on the announcement day.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard